Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Other Non Operating Income (2019 - 2025)

Inmune Bio (INMB) has disclosed Other Non Operating Income for 5 consecutive years, with $166000.0 as the latest value for Q1 2025.

  • Quarterly Other Non Operating Income rose 2175.0% to $166000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $214915.0 through Mar 2025, up 41.95% year-over-year, with the annual reading at $553000.0 for FY2024, 307.12% up from the prior year.
  • Other Non Operating Income hit $166000.0 in Q1 2025 for Inmune Bio, up from -$8000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $166000.0 in Q1 2025 to a low of -$8000.0 in Q1 2021.
  • Historically, Other Non Operating Income has averaged $50000.0 across 3 years, with a median of -$8000.0 in 2021.
  • Biggest five-year swings in Other Non Operating Income: plummeted 136.36% in 2021 and later soared 2175.0% in 2025.
  • Year by year, Other Non Operating Income stood at -$8000.0 in 2021, then changed by 0.0% to -$8000.0 in 2024, then skyrocketed by 2175.0% to $166000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for INMB at $166000.0 in Q1 2025, -$8000.0 in Q1 2024, and -$8000.0 in Q1 2021.